All In MedTech

Device Trial Radar · NCT00746759

Airway Epithelium Gene Expression: AEGIS IDE

Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS IDE

Last checked: Nov 20, 2026Latest source record: Jun 4, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,331

Actual

Start

Feb 2010

Primary completion

Dec 2014

Study completion Feb 2015

Sponsor

Lead sponsor
Allegro Diagnostics, Corp.Not on our public-company list
Sponsor type
Industry
Collaborators
University of Pennsylvania; Columbia University; Temple University; Indiana University; University of Alabama at Birmingham; University of Missouri-Columbia; Louisiana State University Health Sciences Center in New Orleans; University of Wisconsin, Madison; Medical University of South Carolina; National Jewish Health; Overlake Hospital Bellevue WA; Pulmonary and Allergy Associates of New Jersey; Pulmonary Associates of Arizona; William Jennings Bryan Dorn VA Medical Center; Virginia Commonwealth University; Jamaica Hospital Medical Center; North Florida/South Georgia Veterans Health System; Steward St. Elizabeth's Medical Center of Boston, Inc.; University of California, Davis; Yale University; The Cleveland Clinic
First posted
Sep 4, 2008

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.

Conditions

  • Lung Cancer

Interventions

  • Biomarker (not used as an intervention)Device

    This study is an observational study. There is no intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lung Cancer Diagnosis (positive or negative)Time frame: 12 months

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Pulmonary Associates of Arizona

    Phoenix, Arizona

  • University of California- Davis

    Sacramento, California

18 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.